Thomas E. Witzig, Michael B. Tomblyn, Jamal G. Misleh, Ebenezer A. Kio, Robert M. Sharkey, William A. Wegener, David M. Goldenberg. Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma. haematol [Internet]. 2014Nov.3 [cited 2024Apr.19];99(11):1738-45. Available from: https://haematologica.org/article/view/7203